Glaukos (GKOS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
28 May, 2026Opening remarks and agenda
Meeting called to order by the Chair, with a virtual format to enhance stockholder participation.
Agenda and rules of conduct made available on the portal, with instructions for stockholder questions.
Board and executive committee updates
Board members and executive officers introduced, including representatives from the independent auditor.
Shareholder proposals
Three proposals presented: election of two Class II directors, advisory approval of executive compensation, and ratification of the independent auditor.
Board recommended approval of all proposals.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Glaukos
- LCD changes may delay but not derail iDose growth; long-term outlook remains robust.GKOS
Stifel 2026 Virtual Ophthalmology Forum28 May 2026 - Innovative therapies and robust pipeline fuel growth in eye disease treatment and global expansion.GKOS
Investor presentation4 May 2026 - Q1 2026 sales up 41% to $150.6M, guidance raised, driven by iDose TR and Epioxa launches.GKOS
Q1 202630 Apr 2026 - 2025 saw strong growth, robust governance, and ESG progress, with pay tied to performance.GKOS
Proxy filing16 Apr 2026 - Virtual annual meeting to vote on directors, executive pay, and auditor ratification.GKOS
Proxy filing16 Apr 2026 - Market-leading therapies and innovation fuel strong growth and pipeline expansion.GKOS
Investor presentation5 Mar 2026 - Record 2025 sales and Glaucoma growth drive strong 2026 outlook, despite impairment.GKOS
Q4 202518 Feb 2026 - Record revenue and margin gains driven by iDose, with Epioxa launch and payer expansion ahead.GKOS
Stephens Annual Investment Conference3 Feb 2026 - iDose launch accelerates interventional glaucoma shift, with full reimbursement and pipeline growth ahead.GKOS
2024 Truist Securities MedTech Conference3 Feb 2026